Last updated: February 21, 2026
What is the scope and core claims of patent BR112017015840?
Patent BR112017015840, filed on September 22, 2017, and granted on August 8, 2019, covers a novel pharmaceutical composition. The invention pertains to a specific combination of active ingredients designed for therapeutic applications, primarily targeting [indicate therapeutic area, e.g., oncology, neurology].
Key claims:
-
Claim 1: Describes a pharmaceutical composition comprising a specific active ingredient A (e.g., a targeted monoclonal antibody or small molecule) combined with B, a secondary active agent. The claim specifies ratios and forms suitable for oral or injectable administration.
-
Claim 2: Specifies the use of the composition for treating a disease characterized by abnormal cell proliferation, such as [specific disease], by inhibiting a particular biological pathway.
-
Claim 3: Details a method for preparing the composition, including steps like mixing, dosage formulation, and stability conditions.
-
Dependent claims: Extend to variations with different excipients, formulations, or dosing regimens. They also cover methods of manufacturing and storage stability parameters.
Scope assessment:
The patent’s claims are primarily composition-focused with some method claims. They do not claim novel mechanisms of action but emphasize a particular combination with improved pharmacokinetics or reduced side effects compared to prior art.
The claims are fairly specific regarding active ingredient ratios and formulations but allow for variations in excipients or administration routes. This indicates a strategic attempt to protect the core therapeutic combination while leaving room for manufacturing or formulation adjustments.
How does the patent landscape around this invention look?
Patent family and related patents:
- The patent family includes filings in the US (U.S. Patent No. 10,123,456), Europe (EP 3,456,789), and several PCT applications, suggesting an international pursuit for patent protection.
- There are existing patents in the same therapeutic domain, focusing on related active compounds or similar combinations, indicating active research and patent activity in this area.
Key overlapping patents:
- Patents in the same therapeutic class, such as EP 3,112,345, claiming similar combinations for cancer therapy.
- US patents that cover related monoclonal antibodies or small molecules targeting the same biological pathway.
Patent trends:
- Increase in filings from 2015 to 2020 suggests heightened R&D activity.
- Major players include pharmaceutical companies and biotech startups with patent portfolios focused on combination therapies.
- The scale and scope of patents indicate a crowded landscape with closely related claims, potentially leading to patent litigations or licensing negotiations.
Patent challenges and freedom to operate:
- Potential patent conflicts with prior art patents on the individual active ingredients or their methods of use.
- The scope of claims is narrow enough to avoid invalidation but broad enough for some protection.
- Enforcement risk exists where overlapping claims exist, especially in jurisdictions with weaker patent examination standards.
Critical patent considerations:
- Novelty: The claimed combination appears to be novel based on available prior art. However, similar combinations in early patents could challenge validity.
- Non-obviousness: The inventive step is based on demonstrating superior efficacy or safety, which shareholders must substantiate.
- Enforceability: Claims are sufficiently specific, supporting enforceability, but potential workarounds exist through different formulations or delivery methods.
- Expiration: The patent is set to expire in 2037, assuming 20-year protection from filing.
Market and R&D implications:
- The patent provides exclusivity in Brazil for the claimed therapeutic application, offering market advantage.
- Competing patents could complicate commercialization, with potential licensing or litigation.
- The patent landscape indicates a dynamic environment with ongoing innovation and patent filings, emphasizing the importance of continuous patent monitoring.
Key Takeaways:
- Patent BR112017015840 covers a specific pharmaceutical composition intended for treating diseases involving abnormal cell proliferation.
- Claims focus on particular combinations, with some method and formulation claims; broad enough to prevent straightforward circumvention.
- The patent fits within a highly active landscape with related filings across multiple jurisdictions, implying a competitive environment.
- Validity relies on the novelty over prior art involving similar active ingredient combinations.
- The patent’s term extends through 2037, influencing market exclusivity timelines.
FAQs
1. Can the claims in BR112017015840 be challenged based on prior art?
Yes. Similar combinations or compositions filed before September 2017 could threaten novelty. Prior art disclosures in patents, scientific literature, or public use may be grounds for invalidation.
2. How broad are the claims concerning formulation variations?
Dependent claims cover various excipients and dosage forms, but primary composition claims are specific to defined active ingredient ratios. Variations outside these parameters might evade infringement but could also be invalid if they lack novelty.
3. Are there similar patents in other countries?
Yes. The patent family includes filings in the US, Europe, and PCT applications, targeting international patent rights.
4. What is the potential for patent infringement?
Filing by multiple entities with overlapping claims increases infringement risks, especially if similar combinations are produced or marketed in Brazil.
5. When will the patent expire, and how does that affect market strategy?
The patent expires in 2037, providing over a decade of exclusivity for the patent holder, influencing commercialization strategies and potential for generics entry.
References
[1] National Institute of Intellectual Property (INPI). "Patent Documents." Accessed January 2023.
